Approach to the Geriatric Patient with Lung Cancer

tibbi onkoloji ozel 13-4 kapak

Sinan ÜNALa, İlhan ÖZTOPb

aİzmir Kâtip Çelebi Üniversitesi Atatürk Eğitim ve Araştırma Hastanesi, Tıbbi Onkoloji Kliniği, İzmir, TÜRKİYE
bDokuz Eylül Üniversitesi Onkoloji Enstitüsü, Klinik Onkoloji ABD, İzmir, TÜRKİYE

ABSTRACT
The world population is increasing. In addition to the increasing population, the proportion of the elderly population is gradually increasing. Cancer, especially lung cancer, which is our subject, is basically a disease of advanced age. Physiological and some pathological changes caused by aging affect the treatment decision, and the path to be followed may differ according to young people. Systemic treatment and management of lung cancer in the geriatric patient population that we encounter more and more frequently in our practice every day and will be more frequent in the future, has special features. Age should not be a stand-alone criterion in the choice of treatment, just because of age, the patient should not receive less than the care he should receive. Although the number of studies conducted in the geriatric age group is small, subgroup analyzes show that the treatments can give similar results in elderly patients.
Keywords: Lung cancer; geriatric assesment; treatment

Referanslar

  1. Siegel R, Naishadham D, Jemal A. CA Cancer J Clin. 2012;62:10-29. [Crossref]  [PubMed]
  2. Wang S, Wong M, Hamilton N, Davoren JB, Jahan TM, Walter LC. Impact of age and comorbidity on nonsmall-cell lung cancer treatment in older veterans. J Clin Oncol. 2012;30:1447-55. [Crossref]  [PubMed]  [PMC]
  3. Mellemgaard A, Luchtenborg M, Iachina M, et al. Role of comorbidity on survival after radiotherapy and chemotherapy for nonsurgically treated lung cancer. J Thorac Oncol. 2015;10:272-9. [Crossref]  [PubMed]
  4. Repetto L, Fratino L, Audisio RA, et al. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. J Clin Oncol. 2002;20:494-502. [Crossref]  [PubMed]
  5. Atakul E, Akyar İ, Tanyer DK Geriatric Assesment in Oncology: G8 Screening Tool validation and Reliability Study, Turk J Oncol. 2019;34(4):236-42 [Crossref]
  6. Kökoğlu B, Sari YE, Balcioğlu H, Bilge U, Çolak E, Ünlüoğlu İ Turkish Reliability of the vulnerable elderly survey-13 bBiomedical Research 2017, special issue p 513-5.
  7. [Link]
  8. Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, eds. AJCC Cancer Staging Manual 8th ed. Springer International Publishing: American Joint Commission on Cancer; 2017 [cited 2016 Dec 28].
  9. Bendixen M, Jorgensen OD, Kronborg C, Andersen C, Licht PB. Postoperative pain and quality of life after lobectomy via video-assisted thoracoscopic surgery or anterolateral thoracotomy for early stage lung cancer: a randomised controlled trial. Lancet Oncol. 2016;17(6):836-44. [Crossref]  [PubMed]
  10. Kirby TJ, Mack MJ, Landreneau RJ, Rice TW. Lobectomy-video-assisted thoracic surgery versus musclesparing thoracotomy. A randomized trial. J Thorac Cardiovasc Surg. 1995;109(5):997-1001; discussion 1001- 1002 [Crossref]  [PubMed]
  11. Long H, Lin ZC, Lin YB, Situ DR, Wang YN, Rong TH. Quality of life after lobectomy for early stage non-small cell lung cancer - video-assisted thoracoscopic surgery versus minimal incision thoracotomy. Ai Zheng. 2007a;26(6):624-8.
  12. Billmeier SE, Ayanian JZ, He Y, Jaklitsch MT, Rogers SO. Predictors of nursing home admission, severe functional impairment, or death one year after surgery for non-small cell lung cancer. Ann Surg. 2013;257(3):555- 63. [Crossref]  [PubMed]
  13. McGarry RC, Papiez L, Williams M, Whitford T, Timmerman RD. Stereotactic body radiation therapy of early-stage non-small-cell lung carcinoma: phase I study. Int J Radiat Oncol Biol Phys. 2005;63(4):1010-5. [Crossref]  [PubMed]
  14. Baumann P, Nyman J, Hoyer M, et al. Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol. 2009;27(20): 3290-6. [Crossref]  [PubMed]
  15. Guckenberger M, Allgauer M, Appold S, et al. Safety and efficacy of stereotactic body radiotherapy for stage 48 Lung Cancer in Older Adults: Local Treatment 795 1 non-small-cell lung cancer in routine clinical practice: a patterns-of-care and outcome analysis. J Thorac Oncol. 2013;8(8):1050-8. [Crossref]  [PubMed]
  16. Timmerman RD, Hu C, Michalski J, Straube W, Galvin J, Johnstone D, et al. Long-term results of RTOG 0236: a phase II trial of stereotactic body radiation therapy (SBRT) in the treatment of patients with medically inoperable stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2014;90(1):S30. [Crossref]
  17. Haque W, Szeja S, Tann A, Kalra S, Teh BS. Changes in Treatment Patterns and Overall Survival in Patients With Early-Stage NonSmall Cell Lung Cancer in the United States After the Incorporation of Stereotactic Ablative Radiation Therapy: A Population-based Analysis. Am J Clin Oncol. 2018;41(3):259- 66. [Crossref]  [PubMed]
  18. Zhang B, Zhu F, Ma X, et al. Matched-pair comparisons of stereotactic body radiotherapy (SBRT) versus surgery for the treatment of early stage non-small cell lung cancer: a systematic review and meta-analysis. Radiother Oncol. 2014;112(2):250-5. [Crossref]  [PubMed]
  19. Chang JY, Senan S, Paul MA, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol. 2015;16(6):630-7. [Crossref]  [PubMed]
  20. Crabtree TD, Puri v, Robinson C, et al. Analysis of first recurrence and survival in patients with stage I non-small cell lung cancer treated with surgical resection or stereotactic radiation therapy. J Thorac Cardiovasc Surg. 2014;147(4):1183-91; discussion 1191- 82. [Crossref]  [PubMed]  [PMC]
  21. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a metaanalysis using updated data on individual patients from 52 randomised clinical trials. BMJ. 1995;311:899-909. [Crossref]
  22. Jalal SI, Riggs HD, Melnyk A, et al. Updated survival and outcomes for older adults with inoperable stage III nonsmall-cell lung cancer treated with cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel: analysis of a phase III trial from the Hoosier Oncology Group (HOG) and US Oncology. Ann Oncol. 2012;23:1730-8. [Crossref]  [PubMed]
  23. Fruh M, Rolland E, Pignon JP, et al. Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancer. J Clin Oncol. 2008;26:3573-81. [Crossref]  [PubMed]
  24. Burdett S, Pignon JP, Tierney J, et al. Adjuvant chemotherapy for resected early-stage non-small cell lung cancer. Cochrane Database Syst Rev. 2015;2:CD011430.
  25. Gridelli C. The ELvIS trial: a phase III study of singleagent vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer. Elderly Lung Cancer vinorelbine Italian Study. Oncologist. 2001;6(Suppl 1):4-7. [Crossref]  [PubMed]
  26. Frasci G, Lorusso v, Panza N, et al. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced nonsmall-cell lung cancer. J Clin Oncol. 2000;18:2529-36. 27. Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst. 2003;95:362-72. [Crossref]  [PubMed]
  27. Kudoh S, Takeda K, Nakagawa K, et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced nonsmall-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol. 2006;24:3657- 63. [Crossref]  [PubMed]
  28. Tsukada H, Yokoyama A, Goto K, et al. Randomized controlled trial comparing docetaxelcisplatin combination with weekly docetaxel alone in elderly patients with advanced nonsmall-cell lung cancer: Japan Clinical Oncology Group (JCOG) 0207dagger. Jpn J Clin Oncol. 2015;45:88-95. [Crossref]  [PubMed]
  29. Abe T, Takeda K, Ohe Y, et al. Randomized phase III trial comparing weekly docetaxel plus cisplatin versus docetaxel monotherapy every 3 weeks in elderly patients with advanced nonsmall-cell lung cancer: the intergroup trial JCOG0803/WJOG4307L. J Clin Oncol. 2015;33:575-81. [Crossref]  [PubMed]
  30. Quoix E, Zalcman G, Oster JP, et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet. 2011;378:1079-88. [Crossref]  [PubMed]
  31. Carmichael JA, Mak DW, O'Brien M, A Review of Recent Advances in the Treatment of Elderly and Poor Performanca NSCLC Cancers 2018;10:236. [Crossref]  [PubMed]  [PMC]
  32. Weiss GJ, Langer C, Rosell R, Hanna N, Shepherd F, Einhorn LH, et al. Elderly patients benefit from second-line cytotoxic chemotherapy: A subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer. J. Clin. Oncol. 2006;24:4405-11. [Crossref]  [PubMed]
  33. Caprario LC, Kent DM, Strauss GM. Effects of chemotherapy on survival of elderly patients with small-cell lung cancer: analysis of the SEER-medicare database. J Thorac Oncol. 2013;8:1272-81. [Crossref]  [PubMed]  [PMC]
  34. Ardizzoni A, Favaretto A, Boni L, et al. Platinumetoposide chemotherapy in elderly patients with small-cell lung cancer: results of a randomized multicenter phase II study assessing attenuated-dose or fulldose with lenograstim prophylaxis - a Forza Operativa Nazionale Italiana Carcinoma Polmonare and Gruppo Studio Tumori Polmonari veneto (FONICAP-GSTPv) study. J Clin Oncol. 2005;23:569-75. [Crossref]  [PubMed]
  35. Souhami RL, Spiro SG, Rudd RM, et al. Fiveday oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy. J Natl Cancer Inst. 1997;89:577-80. [Crossref]  [PubMed]
  36. Okamoto H, Watanabe K, Kunikane H, et al. Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poorrisk patients with extensive disease small-cell lung cancer: JCOG 9702. Br J Cancer. 2007;97:162-9. [Crossref]  [PubMed]  [PMC]
  37. Horn L, Mansfield AS, Szczesna A, Havel L, Krzakowski M, et al. First-Line Atezolizumab plus chemotherapy in Extensive Stage Small Cell Lung Cancer N Engl J Med. 2018; 379:2220-9. [Crossref]  [PubMed]
  38. Mok T, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma. N. Engl. J. Med. 2009;361:947-57. [Crossref]  [PubMed]
  39. Zhou C, Wu Y, Chen G, Feng J, Liu XQ, Wang C, et al. Erlotinib versus chemotherapy as firstline treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12,735-42. [Crossref]  [PubMed]
  40. Rosell R, Carcereny E, Gervais R, vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239-46. [Crossref]  [PubMed]
  41. Lee SM, Khan I, Upadhyay S, Lewanski C Falk S, Skailes G, et al. First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): A double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2012;13:1161-70. [Crossref]  [PubMed]
  42. Sequist L, Yang J, Yamamoto N, O'Byrne K, Hirsh v, Mok T, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J. Clin. Oncol. 2013;31:3327-34. [Crossref]  [PubMed]
  43. Wu Y, Zhou C, Hu C, Feng J, Lu S, Huang Y, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): An open-label, randomised phase 3 trial. Lancet Oncol. 2014;15:213-22. [Crossref]  [PubMed]
  44. Park K, Tan E, O'Byrne K, Zhang L, Boyer M, Mok T, et al. Afatinib versus gefitinib as firstline treatment of patients with EGFR mutationpositive non-small-cell lung cancer (LUX-Lung 7): A phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016;17:577-89. [Crossref]  [PubMed]
  45. Mok T, Wu Y, Ahn M, Garassino MC, Kim HR, Ramalingam SS, et al. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N. Engl. J. Med. 2017;376:629- 40. [Crossref]  [PubMed]  [PMC]
  46. Soria J, Ohe Y, vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2018;378:113-25. [Crossref]  [PubMed]
  47. Shaw A, Kim D, Nakagawa K, Seto T, Crino L, Ahn M, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N. Engl. J. Med. 2013;368:2385-94. [Crossref]  [PubMed]
  48. Solomon B, Mok T, Kim D, Wu Y, Nakagawa K, Mekhail T, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N. Engl. J. Med. 2014;371:2167-77. [Crossref]  [PubMed]
  49. Soria J, Tan D, Chiari R, Wu Y, Paz-Ares L, Wolf J, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALKrearranged non-small-cell lung cancer (ASCEND-4): A randomised, open-label, phase 3 study. Lancet. 2017;389:917-29. [Crossref]  [PubMed]
  50. Shaw A, Kim T, Crinò L, Gridelli C, Kiura K, Liu G, et al. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): A randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2017;18:874-86. [Crossref]  [PubMed]
  51. Hida T, Nokihara H, Kondo M, Kim YH, Azuma K, Seto T, et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): An open-label, randomised phase 3 trial. Lancet. 2017;390:29-39. [Crossref]  [PubMed]
  52. Peters S, Camidge D, Shaw A, Gadgeel S, Ahn JS, Kim DW, et al. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2017;377:829- 38. [Crossref]  [PubMed]
  53. Borghaei H, Paz-Ares L, Horn L, Spiegel DR, Steins M, Ready NE, et al Nivolumab versus Docetaxel in Advanced Nonsquamous NonSmall-Cell Lung Cancer . N. Engl. J. Med. 2015;373:1627-39. [Crossref]  [PubMed]  [PMC]
  54. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WEE, Poddubskaya E, et. al Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2015;373:123-35. [Crossref]  [PubMed]  [PMC]
  55. Hellmann MD, Ciuleanu T-E, Pluzanski A, Lee JS, Otterson GA, Audigier-valette C, et al. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. N. Engl. J. Med. 2018;378:2093-104. [Crossref]  [PubMed]  [PMC]
  56. Spigel D, Schwartzberg L, Waterhouse D, Chandler J, Hussein M, Jotte R, et al. Is Nivolumab Safe and Effective in Elderly and PS2 Patients with Non-Small Cell Lung Cancer (NSCLC)? Results of CheckMate 153. J. Thorac. Oncol. 2017;12:S1287-S8. [Crossref]
  57. Popat S, Ardizzoni A, Ciuleanu T, Cobo Dols M, Laktionov K, Szilasi M, et al. Nivolumab in previously treated patients with metastatic squamous NSCLC: Results of a European single-arm, phase 2 trial (CheckMate 171) including patients aged ≥ 70 years and with poor performance status. Ann. Oncol. 2017;8:mdx380.006. [Crossref]
  58. Hebst RS, Baas P, Kim DW, Felip E, PerezGarcia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010) : a rondomised controlled trial, Lancet. 2016;387:1540-50. [Crossref]  [PubMed]
  59. Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2016;375:1823-33. [Crossref]  [PubMed]
  60. Gandhi L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2018;378:2078-92. [Crossref]  [PubMed]
  61. Rittmeyer A, Barlesi F,Waterkamp D, Park K, Ciardello F, Pawel Jv, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled tiral, Lancet. 2017;389:255-65. [Crossref]  [PubMed]
  62. Socinski M, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, et al. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC, N Engl J Med. 2018;378:2288-301. [Crossref]  [PubMed]